How to buy Johnson-and-Johnson (JNJ) stocks

Johnson-and-Johnson is a drug manufacturers - general business based in the US. Johnson-and-Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $166.69 – a decrease of 0.35% over the previous week. Johnson-and-Johnson employs 138,100 staff and has a trailing 12-month revenue of around $88.8 billion.

Our top picks for where to buy Johnson-and-Johnson stock

Buy Johnson-and-Johnson stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Johnson-and-Johnson stock price (NYSE: JNJ)

Use our graph to track the performance of JNJ stocks over time.

Johnson-and-Johnson stocks at a glance

• Key figures

Information last updated 2025-03-06.

Latest market close	$166.69
52-week range	$138.68 - $169.99
50-day moving average more info button	$151.91
200-day moving average more info button	$154.92
Wall St. target price	$169.07
PE ratio more info button	28.6408
Dividend yield more info button	$4.91 (2.99%)
Earnings per share (TTM) more info button	$5.79

Is it a good time to buy Johnson-and-Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Johnson-and-Johnson price performance over time

Historical closes compared with the close of $166.69 from 2025-03-07

1 week (2025-03-03)	-0.35%
1 month (2025-02-10)	8.07%
3 months (2024-12-10)	11.70%
6 months (2024-09-10)	-0.41%

1 year (2024-03-08)	4.49%
2 years (2023-03-10)	16.96%
3 years (2022-03-10)	7.35%
5 years (2020-03-10)	35.41%

Is Johnson-and-Johnson stock undervalued or overvalued?

Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson-and-Johnson's P/E ratio

Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Johnson-and-Johnson shares trade at around 29x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

Johnson-and-Johnson's PEG ratio

Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.126. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Johnson-and-Johnson's EBITDA

Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $29.9 billion.

The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson-and-Johnson financials

Revenue TTM	$88.8 billion
Operating margin TTM	18.15%
Gross profit TTM	$61.8 billion
Return on assets TTM	8.13%
Return on equity TTM	20.06%
Profit margin	15.84%
Book value	$29.70
Market Capitalization more info button	$399.3 billion

TTM: trailing 12 months

Johnson-and-Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson-and-Johnson's total ESG risk score

Total ESG risk: 35.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson-and-Johnson's environmental score

Environmental score: 3.79/100

Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson-and-Johnson's social score

Social score: 25.14/100

Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson-and-Johnson's governance score

Governance score: 14.87/100

Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson-and-Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.

Environmental, social, and governance (ESG) summary

Johnson & Johnson was last rated for ESG on: 2019-01-01.

Total ESG score	35.8
Total ESG percentile	72.38
Environmental score	3.79
Environmental score percentile	7
Social score	25.14
Social score percentile	7
Governance score	14.87
Governance score percentile	7
Level of controversy	4

Johnson-and-Johnson stock dividends

Dividend payout ratio: 49.65% of net profits

Recently Johnson-and-Johnson has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.91 per share.

While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.

Johnson-and-Johnson's most recent dividend payout was on 3 March 2025. The latest dividend was paid out to all shareholders who bought their stocks by 17 February 2025 (the "ex-dividend date").

Have Johnson-and-Johnson's stocks ever split?

Johnson-and-Johnson's stocks were split on a 2:1 basis on 12 June 2001 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Johnson-and-Johnson stocks, which in turn could have impacted Johnson-and-Johnson's stock price.

Johnson-and-Johnson stock price volatility

Over the last 12 months, Johnson-and-Johnson's stocks have ranged in value from as little as $138.681 up to $169.99. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.463. This would suggest that Johnson-and-Johnson's stocks are less volatile than average (for this exchange).

Johnson-and-Johnson overview

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Johnson-and-Johnson is owned by insiders or institutions?
Currently 0.454% of Johnson-and-Johnson stocks are held by insiders and 73.573% by institutions. How many people work for Johnson-and-Johnson?
Latest data suggests 138,100 work at Johnson-and-Johnson. When does the fiscal year end for Johnson-and-Johnson?
Johnson-and-Johnson's fiscal year ends in December. Where is Johnson-and-Johnson based?
Johnson-and-Johnson's address is: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 What is Johnson-and-Johnson's ISIN number?
Johnson-and-Johnson's international securities identification number is: US4781601046 What is Johnson-and-Johnson's CUSIP number?
Johnson-and-Johnson's Committee on Uniform Securities Identification Procedures number is: 478160104

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.